180 related articles for article (PubMed ID: 36746394)
1. The association of blood ctDNA levels to mutations of marker genes in colorectal cancer.
Bai F; Du Q; Zou Q; Xu L; Dong W; Lv X; Han X; Zhou H; Zhang C; Lu T
Cancer Rep (Hoboken); 2023 Apr; 6(4):e1782. PubMed ID: 36746394
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients.
Yang YC; Wang D; Jin L; Yao HW; Zhang JH; Wang J; Zhao XM; Shen CY; Chen W; Wang XL; Shi R; Chen SY; Zhang ZT
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29914973
[TBL] [Abstract][Full Text] [Related]
3. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated DNA mutation detection in individuals undergoing colonoscopy.
Fleshner P; Braunstein GD; Ovsepyan G; Tonozzi TR; Kammesheidt A
Cancer Med; 2018 Jan; 7(1):167-174. PubMed ID: 29125240
[TBL] [Abstract][Full Text] [Related]
6. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.
Nassar FJ; Msheik ZS; Nasr RR; Temraz SN
Clin Epigenetics; 2021 May; 13(1):111. PubMed ID: 34001239
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
Arisi MF; Dotan E; Fernandez SV
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer.
Luo H; Zhao Q; Wei W; Zheng L; Yi S; Li G; Wang W; Sheng H; Pu H; Mo H; Zuo Z; Liu Z; Li C; Xie C; Zeng Z; Li W; Hao X; Liu Y; Cao S; Liu W; Gibson S; Zhang K; Xu G; Xu RH
Sci Transl Med; 2020 Jan; 12(524):. PubMed ID: 31894106
[TBL] [Abstract][Full Text] [Related]
9. Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1.
Symonds EL; Pedersen SK; Yeo B; Al Naji H; Byrne SE; Roy A; Young GP
Mol Oncol; 2022 May; 16(10):2031-2041. PubMed ID: 35000264
[TBL] [Abstract][Full Text] [Related]
10. A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study.
Unseld M; Belic J; Pierer K; Zhou Q; Moser T; Bauer R; Piringer G; Gerger A; Siebenhüner A; Speicher M; Heitzer E; Prager GW
Int J Cancer; 2021 Mar; 148(6):1452-1461. PubMed ID: 32949150
[TBL] [Abstract][Full Text] [Related]
11. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
[TBL] [Abstract][Full Text] [Related]
12. Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer.
Narayan RR; Goldman DA; Gonen M; Reichel J; Huberman KH; Raj S; Viale A; Kemeny NE; Allen PJ; Balachandran VP; D'Angelica MI; DeMatteo RP; Drebin JA; Jarnagin WR; Kingham TP
Ann Surg Oncol; 2019 Jun; 26(6):1824-1832. PubMed ID: 30706231
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
Tie J; Cohen JD; Lo SN; Wang Y; Li L; Christie M; Lee M; Wong R; Kosmider S; Skinner I; Wong HL; Lee B; Burge ME; Yip D; Karapetis CS; Price TJ; Tebbutt NC; Haydon AM; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Popoli M; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Int J Cancer; 2021 Feb; 148(4):1014-1026. PubMed ID: 32984952
[TBL] [Abstract][Full Text] [Related]
14. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
[TBL] [Abstract][Full Text] [Related]
15. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
16. Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey.
Basile D; Gallois C; Puglisi F; Cohen R; Goere D; Aprile G; Lepage C; Laurent-Puig P; Di Maio M; Lecomte T; Pernot S; Zaanan A; Taieb J
Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101681. PubMed ID: 33785445
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
[TBL] [Abstract][Full Text] [Related]
18. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
